Date: 2014-12-17
Type of information: Grant
Company: IMMUNOSHAPE consortium (Midatech Pharma (UK)
Investors:
Amount: €3.8 million
Funding type: grant
Planned used: The grant will fund a project entitled “IMMUNOSHAPE” which aims to train a new generation of scientists capable of applying state of the art synthesis and screening technology to develop new lead structures for highly selective glycan based multivalent immunotherapeutics for the treatment of cancer, autoimmune diseases and allergy. Midatech is applying its glycan coated gold nanoparticle (GNP) technology platform to the treatment of diabetes, a range of orphan oncology indications including brain, liver, pancreatic and ovarian cancer and neurological/ophthalmologic conditions, most of which have multi-$100 million or multi-$billion markets.
Others: * On December 17, 2014, Midatech Pharma, a nanomedicine company developing and commercialising multiple therapeutic products to enhance the delivery of medicines in major diseases with high unmet medical needs, announced that a consortium of academic and industry groups including Midatech has been awarded a €3.8 million European Union grant. Of the total grant, €227,000 is for Midatech directly, with the balance going to the consortium of nine leading academic groups with expertise in automated solid-phase carbohydrate synthesis, microarray based high-throughput screening technology, tumour immunology, structural glycobiology, multivalent systems and medicinal chemistry along with 4 industrial partners active in nanomedicine, immunotherapy, medicinal device development.
Therapeutic area: Allergic diseases - Autoimmune diseases - Cancer - Oncology
